VRCA.NASDAQVerrica Pharmaceuticals INC
10-K: Verrica Pharmaceuticals Reports FY2024 Results, Navigates Financial Uncertainty
Sentiment:
Annual Results
Verrica Pharmaceuticals announces its FY2024 results, highlighting YCANTH sales growth while acknowledging substantial doubt about its ability to continue as a going concern.
Capital raiseThe company states that it will need substantial additional funding to meet its financial obligations and to pursue its business objectives.The company plans to secure additional capital in the future through equity or debt financings, partnerships, or other sources to carry out the company's planned commercial and development activities.The company's ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the disruptions to, and volatility in, the credit and financial markets in the United States and worldwide.
Worse than expectedThe company's net losses increased from 2023 to 2024.The company has substantial doubt about its ability to continue as a going concern.The company's research and development expenses decreased, which may indicate a slowdown in development activities.
Summary
- Verrica Pharmaceuticals reported a net loss of $76.6 million for the year ended December 31, 2024, compared to a net loss of $67.0 million in 2023.
- The company's accumulated deficit reached $307.0 million as of December 31, 2024.
- Product revenue, net, increased to $6.6 million in 2024 from $4.7 million in 2023, driven by sales of YCANTH.
- Collaboration revenue from the Torii Agreement was $1.0 million in 2024, up from $0.5 million in 2023.
- Selling, general, and administrative expenses rose to $58.8 million in 2024 from $47.3 million in 2023, due to increased commercial activities and severance costs.
- Research and development expenses decreased to $11.8 million in 2024 from $20.3 million in 2023, reflecting reduced clinical costs for VP-315 and YCANTH.
- The company's cash and cash equivalents totaled $46.3 million as of December 31, 2024.
- Due to recurring losses and debt obligations, there is substantial doubt about Verrica's ability to continue as a going concern within one year.
- The company is seeking additional funding through equity, debt, partnerships, or other sources to support its commercial and development activities.
- Verrica is developing YCANTH for common warts, with Phase 3 trials anticipated to begin in mid-2025, and VP-315 for basal cell carcinoma, with Phase 3 trial plans pending end-of-phase 2 meeting minutes.
Sentiment
Score: 4
Explanation: The document presents a mixed picture. While there is revenue growth and progress in clinical trials, the going concern warning and increasing losses weigh heavily on the overall sentiment.
Positives
- YCANTH achieved FDA approval and commercial launch, generating revenue.
- Positive clinical trial results for VP-315 in treating basal cell carcinoma.
- Collaboration with Torii Pharmaceutical for development and commercialization in Japan.
- Secured a permanent J-code for YCANTH, improving reimbursement prospects.
- Significant insurance coverage secured for YCANTH, reaching approximately 225 million lives.
- Strong inventory position of YCANTH applicators and API.
Negatives
- Significant net losses and accumulated deficit.
- Substantial doubt about the company's ability to continue as a going concern.
- Reliance on additional funding to sustain operations.
- Increased selling, general, and administrative expenses.
- Potential competition from compounded cantharidin and other therapies.
- Risk of product liability lawsuits.
Risks
- Inability to secure additional funding to meet financial obligations.
- Failure to successfully develop and commercialize product candidates.
- Substantial competition in the market.
- Dependence on third parties for raw materials and manufacturing.
- Potential for product liability lawsuits.
- Failure to comply with healthcare laws and regulations.
- Volatility in the trading price of common stock.
- Potential delisting from Nasdaq.
Future Outlook
The company plans to continue commercializing YCANTH, developing YCANTH for common warts, and advancing VP-315 for BCC. They are also seeking additional funding to support these activities.
Management Comments
- Management has concluded that there is substantial doubt regarding the company's ability to continue as a going concern within one year after the date these financial statements are issued.
- Management plans to secure additional capital in the future through equity or debt financings, partnerships, or other sources to carry out the company's planned commercial and development activities.
Industry Context
The pharmaceutical industry is highly competitive, with companies facing competition from major pharmaceutical, specialty pharmaceutical, and biotechnology companies, as well as compounding facilities and academic institutions. Verrica competes with existing treatments and new treatments that may become available in the future.
Comparison to Industry Standards
- The document does not provide specific comparisons to industry standards or comparable companies regarding revenue, profitability, or other financial metrics.
- The document mentions that many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials even after achieving promising results in preclinical testing and earlier-stage clinical trials.
- The document mentions that the company faces competition from major pharmaceutical and specialty pharmaceutical companies, compounding facilities, academic institutions, and governmental agencies and public and private research institutions.
Legal Proceedings
- The company is involved in a putative class action lawsuit and a putative stockholder derivative lawsuit related to alleged violations of federal securities laws and breaches of fiduciary duties.
- The company settled litigation with Dormer Laboratories Inc., discontinuing the sale of cantharidin-containing products in the United States.
Stakeholder Impact
- Shareholders face potential dilution from future equity offerings and the risk of stock price volatility.
- Employees may experience job insecurity due to cost-cutting measures and the company's financial instability.
- Customers may be affected by potential disruptions in the supply of YCANTH.
- Creditors face increased risk due to the company's going concern uncertainty.
Next Steps
- Continue commercialization of YCANTH for molluscum contagiosum.
- Advance YCANTH for common warts into Phase 3 trials.
- Advance VP-315 for BCC and potentially additional dermatological oncology indications.
- Seek additional funding through various means.
Key Dates
| Date | Description |
|---|---|
| July 3, 2013 | Verrica Pharmaceuticals Inc. incorporated in Delaware. |
| July 16, 2018 | Supply Agreement with Funing County Development Brucea Javanica Professional Cooperatives. |
| June 2019 | Positive topline results from COVE-1 Phase 2 trial of YCANTH for common warts. |
| August 7, 2020 | Entered into the Lytix License Agreement. |
| March 17, 2021 | Entered into the Torii Agreement. |
| November 2021 | FDA accepted IND for VP-315. |
| April 2022 | Dosed first patient in Phase 2 trial of VP-315 in BCC. |
| July 25, 2022 | Torii dosed first patient in Phase 3 trial of YCANTH (TO-208) for molluscum in Japan. |
| July 21, 2023 | YCANTH (VP-102) approved by FDA for molluscum contagiosum. |
| July 26, 2023 | Entered into Credit Agreement with OrbiMed and borrowed $50.0 million. |
| August 2023 | Commercial launch of YCANTH (VP-102) in the United States. |
| November 6, 2023 | Type C meeting with FDA on clinical development plan for YCANTH's (VP-102) Common Warts indication. |
| December 2023 | FDA issued Guidance for Industry addressing the criteria by which the FDA intends to evaluate whether there exists a clinical need for compounding with a bulk drug substance. |
| January 2024 | Ligand Pharmaceuticals received FDA approval for Zelsuvmi. |
| April 1, 2024 | YCANTH (VP-102) is reimbursed under a permanent J-code (J7354). |
| May 14, 2024 | Entered into the First Amendment to the Torii Agreement. |
| August 2024 | Announced preliminary positive results from VP-315 Phase 2 trial. |
| October 2024 | Updated VP-315 Phase 2 trial data with complete data set. |
| November 2024 | Reported additional data from VP-315 Phase 2 trial based on post-hoc analysis on calculated Objected Response Rate. |
| November 2024 | Closed an underwritten offering of common stock and warrants for net proceeds of $39.6 million. |
| December 2024 | Torii submitted a New Drug Application for TO-208 for the treatment of molluscum in Japan. |
| December 31, 2024 | Based on net revenue attributable to YCANTH on a trailing 12-month basis not meeting a specified amount set forth in the Credit Agreement, the Company became obligated to start making principal payments starting on January 1, 2025. |
| January 24, 2025 | Received a letter from Nasdaq, notifying the Company that the listing of its common stock was not in compliance with Nasdaq Listing Rule 5450(a)(1). |
| First half of 2025 | Expect to report genomic and immune response data from the VP-315 Phase 2 trial and to receive minutes from an end-of-phase 2 meeting. |
| Mid-2025 | Anticipate Phase 3 trial of YCANTH (VP-102) for common warts could begin. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.